Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and Adolescents

Exclusion Criteria

• •Prior ifosfamide, carboplatin, etoposide (ICE) therapy, with or without an anti-CD20 antibody, or history of hypersensitivity to any components of RICE
• •Known active central nervous system or leptomeningeal lymphoma or within 4 weeks from the last intrathecal therapy prior to the required diagnostic lumbar puncture (LP) for this study
• •Disease progression within 6 months from last anti-CD20 therapy
• •Ongoing toxicity from prior cytotoxic therapy (last dose at least 3 weeks prior to study entry)
• •Less than 4 half-lives from the last dose of previous targeted therapy and ongoing acute toxicity of prior targeted therapy
• •Active infection with human immunodeficiency virus (HIV), cytomegalovirus (CMV), hepatitis B virus (HBV), or hepatitis C virus (HCV) based on screening serology and polymerase chain reaction (PCR) results
• •Evidence of systemic bacterial, fungal, or viral infection at the time of treatment start (Day 1)
• •Ongoing or history of drug-induced pneumonitis
• •Ongoing or history of inflammatory bowel disease
• •Pregnancy or breastfeeding
• •Currently receiving other anti-cancer or other investigational drug
• •Prior solid organ transplantation
• •Prior allogeneic stem cell transplantation within 60 days or active acute graft versus host disease (GVHD) Grade 3 or higher
• •Known hypersensitivity to idelalisib, the metabolites, or formulation excipients
• •Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the participant unsuitable for the study or unable to comply with the study requirements